Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Exagen (NASDAQ:XGN) and maintained a $6 price target.
August 22, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Exagen, maintaining a $6 price target.
The news is directly about Exagen and its rating by Cantor Fitzgerald. The reiteration of an Overweight rating and maintenance of a $6 price target suggests that the analyst sees potential in the stock, but it doesn't necessarily mean the stock price will move in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100